AOD-9604 for Fatty Liver Support

Introduction

Non-alcoholic fatty liver disease (NAFLD) has become one of the most common liver conditions in the developed world. Fat accumulates in liver cells, impairing function and potentially progressing to inflammation (NASH), fibrosis, and cirrhosis. The liver is not meant to store fat -- it is meant to process and export it.

AOD-9604 is a modified fragment of human growth hormone that retains the fat-burning properties of GH without the negative effects on blood sugar and cell proliferation. Originally developed for obesity, researchers are now exploring its potential for reducing hepatic fat accumulation.

In this article, you will learn how AOD-9604 interfaces with liver fat metabolism, what the research suggests about its hepatic effects, and how FixMyT can help you understand whether liver fat may be affecting your metabolic health. If fatty liver has been a concern, this research is directly relevant.

Understanding the Liver: The Filter of Your Metabolism

The Liver node in the FixMyT metabolic tree occupies Level 2, downstream from the Gut and Mitochondria, and upstream of the Thyroid and Estrogen pathways. Its subtitle "Filter" describes one function, but the liver is also a metabolic processing center for fats, carbohydrates, and proteins.

The Liver node encompasses:

• Fat metabolism: Processing dietary fat and exporting triglycerides
• Hormone clearance: Eliminating estrogen and other hormones
• T4 to T3 conversion: Activating thyroid hormone
• Bile production: Supporting fat digestion and hormone excretion

When fat accumulates in the liver beyond normal levels (>5% of liver weight), function begins to decline. NAFLD impairs:

• Insulin sensitivity (contributing to metabolic syndrome)
• Thyroid hormone conversion (affecting metabolic rate)
• Hormone clearance (potentially worsening estrogen dominance)
• Overall metabolic efficiency

The FixMyT interventions for the Liver node include Choline for fat export, coffee for bile flow, and avoiding alcohol. But when hepatic fat accumulation is significant, interventions targeting fat metabolism become relevant -- and that is where AOD-9604 enters the picture.

What Is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to amino acids 176-191 of human growth hormone, with an added tyrosine at the N-terminus. It was developed by Metabolic Pharmaceuticals in Australia specifically to isolate GH's fat-burning effects.

Key characteristics:

• Origin: Modified fragment of human growth hormone
• Classification: Lipolytic peptide
• Molecular weight: ~1800 Da
• Half-life: 30-60 minutes
• Administration: Subcutaneous (250-500 mcg daily, fasted)

What makes AOD-9604 unique is what it does NOT do:

• Does NOT increase IGF-1 (no cancer promotion concern)
• Does NOT cause insulin resistance (unlike full GH)
• Does NOT promote cell proliferation
• Received GRAS (Generally Recognized as Safe) status from FDA in 2016

For complete technical details, see the full AOD-9604 profile on PepGuide.

How AOD-9604 Supports Liver Function

AOD-9604's relevance to liver health comes through its effects on fat metabolism.

1. Lipolysis Stimulation

AOD-9604 stimulates the breakdown of triglycerides:

• Activates beta-3 adrenergic receptors
• Stimulates hormone-sensitive lipase
• Increases triglyceride breakdown into free fatty acids
• Promotes fat oxidation

For fatty liver specifically, this means mobilizing the fat that has accumulated in hepatocytes and making it available for oxidation.

2. Lipogenesis Inhibition

Beyond promoting fat breakdown, AOD-9604 inhibits the creation of new fat:

• Inhibits lipogenic enzymes
• Reduces new fat cell formation
• Prevents triglyceride synthesis
• Decreases fat storage

This two-pronged approach -- increased breakdown plus decreased synthesis -- addresses fatty liver from both directions.

3. No IGF-1 Increase

Unlike full-length growth hormone, AOD-9604 does not increase IGF-1 levels. This is relevant for the liver because:

• No growth factor-mediated liver cell proliferation concerns
• No increase in insulin resistance (which worsens NAFLD)
• Safer profile for long-term use

4. Preclinical Evidence for Liver Fat Reduction

Research published in Endocrinology (2001) demonstrated that AOD-9604 reduced body fat, including liver triglycerides, in obese mice and rats. The treated animals showed significantly lower hepatic fat content without the metabolic disruptions seen with full GH.

5. Metabolic Profile Improvement

By reducing overall adiposity and specifically hepatic fat, AOD-9604 may improve the metabolic markers often disrupted in NAFLD:

• Improved insulin sensitivity
• Better lipid profiles
• Reduced inflammatory markers
• Enhanced liver enzyme levels

What Real People Are Saying

AOD-9604 is primarily discussed for body composition, but hepatic effects have been noted:

"Using AOD-9604 for stubborn visceral fat. After 12 weeks, imaging showed reduced liver density -- meaning less fat infiltration. ALT also improved from mildly elevated to normal range. The internal fat reduction is real." — u/visceral_fat_loss on r/Peptides

"My functional medicine doc recommended AOD-9604 as part of a fatty liver protocol. Combined with dietary changes and Choline supplementation. Fibroscan improved significantly over 6 months. Hard to attribute to any single factor, but the combination worked." — u/nafld_protocol on r/Supplements

"The GRAS status is reassuring -- FDA determined it safe for food use. For fatty liver specifically, the mechanism makes sense: promote fat mobilization from the liver without the insulin resistance that full GH would cause." — u/mechanism_focus on r/Nootropics

These are individual experiences. NAFLD is a serious condition that requires medical monitoring and comprehensive treatment.

Monitoring Your Liver Health with FixMyT

Understanding liver fat requires looking at metabolic context. FixMyT provides a framework for assessing the Liver node within the broader metabolic picture.

The FixMyT symptoms quiz identifies markers relevant to liver function:

• Estrogen dominance symptoms (may indicate liver burden)
• Poor alcohol tolerance (liver processing capacity)
• Sluggish digestion (bile flow issues)
• Weight accumulation, especially central (associated with hepatic fat)

The visual metabolic tree shows how the Liver connects to Nutrition and Mitochondria upstream (energy for fat metabolism) and affects Thyroid and Estrogen downstream. Fatty liver impairs this entire cascade.

If you are considering AOD-9604 for fatty liver support, understanding your baseline is essential. FixMyT helps you see how the Liver node fits into your overall metabolic state.

Research and Considerations

AOD-9604's research base for fat loss is substantial, with emerging interest in liver applications:

What the evidence supports:

• Lipolytic activity reducing body fat (clinical trials)
• No IGF-1 increase or insulin resistance (key safety features)
• Reduced liver triglycerides in animal models
• GRAS status indicating safety profile

What needs more research:

• Clinical trials specifically for NAFLD
• Long-term effects on liver histology
• Optimal dosing for hepatic fat reduction
• Comparison to established NAFLD treatments

Important consideration: AOD-9604 is on the WADA prohibited list (S2 category). Athletes need to be aware of this status.

The most promising context for AOD-9604 in fatty liver is as part of a comprehensive approach including dietary changes (reduced fructose, seed oils), adequate Choline intake, exercise, and weight management.

Disclaimer

This article is for educational and research purposes only. AOD-9604 is not FDA-approved as a therapeutic drug, though it has GRAS status for food use. Nothing in this article constitutes medical advice or a recommendation to use any substance.

Non-alcoholic fatty liver disease requires proper medical diagnosis and monitoring. If you suspect fatty liver or have abnormal liver enzymes, consult with a hepatologist or qualified healthcare provider.

Individual responses vary significantly. The information here reflects current research as of the publication date.

Learn More

• Full AOD-9604 Profile on PepGuide - Complete technical details
• BPC-157 for Liver Protection - Tissue repair approach
• Glutathione: The Master Liver Detoxifier - Detox support
• FixMyT Metabolic Assessment - Understand your liver and metabolic baseline

References

1. Ng FM, et al. "Metabolic effects of a synthetic peptide analogue of growth hormone 177-191." Hormone and Metabolic Research. 2000;32(1):19-26.

2. Heffernan M, et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and rats." Endocrinology. 2001;142(12):5182-5189.

3. FDA. "GRAS Notice 000617: AOD-9604." FDA GRAS Notices. 2016.

4. Obesity Peptide Research. "Growth Hormone Fragments in Metabolic Disease." Obesity Research Reviews. 2025.

5. Younossi ZM, et al. "Global epidemiology of nonalcoholic fatty liver disease." Nature Reviews Gastroenterology & Hepatology. 2018;15(1):11-20.